Suplemen Omega-3 tidak menjaga kesehatan otak, menurut sebuah studi baru dalam Journal of American Medical Association. Peneliti diikuti 4.000 pasien selama lima tahun dan menemukan bahwa suplemen tidak memperlambat penurunan kognitif.
Ini bukan pertama kalinya manfaat dari suplemen omega-3–biasanya berasal dari minyak ikan–telah terbantahkan. Studi terbaru yang dipublikasikan dalam New England Journal of Medicine, Journal of American Medical Association, dan Archives of Internal Medicine menemukan bahwa semua melengkapi dengan asam lemak omega-3 tidak meningkatkan kesehatan jantung. Suplemen omega-3 juga dapat meningkatkan risiko pria terkena kanker prostat.
Asam lemak omega-3 yang penting dalam fungsi normal dari semua jaringan tubuh, tetapi mereka terbaik diperoleh melalui pola makan nabati, tidak suplemen minyak ikan. Ambil kami Infographic omega-3 untuk mempelajari lebih lanjut tentang sumber yang paling menyehatkan.
Omega-3 supplements don’t keep your brain healthy, according to a new study in the Journal of the American Medical Association. Researchers followed 4,000 patients over a five-year period and found that the supplements don’t slow cognitive decline.
It’s not the first time the supposed benefits of omega-3 supplements—typically derived from fish oil—have been debunked. Recent studies published in the New England Journal of Medicine, Journal of the American Medical Association, and Archives of Internal Medicine all found that supplementing with omega-3 fatty acids does not improve heart health. Omega-3 supplements may also increase men’s risk of developing prostate cancer.
Omega-3 fatty acids are important in the normal functioning of all tissues of the body, but they are best obtained through a plant-based diet, not fish oil supplements.
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive FunctionThe AREDS2 Randomized Clinical Trial
Importance Observational data have suggested that high dietary intake of saturated fat and low intake of vegetables may be associated with increased risk of Alzheimer disease.
Objective To test the effects of oral supplementation with nutrients on cognitive function.
Design, Setting, and Participants In a double-masked randomized clinical trial (the Age-Related Eye Disease Study 2 [AREDS2]), retinal specialists in 82 US academic and community medical centers enrolled and observed participants who were at risk for developing late age-related macular degeneration (AMD) from October 2006 to December 2012. In addition to annual eye examinations, several validated cognitive function tests were administered via telephone by trained personnel at baseline and every 2 years during the 5-year study.
Interventions Long-chain polyunsaturated fatty acids (LCPUFAs) (1 g) and/or lutein (10 mg)/zeaxanthin (2 mg) vs placebo were tested in a factorial design. All participants were also given varying combinations of vitamins C, E, beta carotene, and zinc.
Main Outcomes and Measures The main outcome was the yearly change in composite scores determined from a battery of cognitive function tests from baseline. The analyses, which were adjusted for baseline age, sex, race, history of hypertension, education, cognitive score, and depression score, evaluated the differences in the composite score between the treated vs untreated groups. The composite score provided an overall score for the battery, ranging from −22 to 17, with higher scores representing better function.
Results A total of 89% (3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and 93.6% (3501/3741) underwent cognitive function testing. The mean (SD) age of the participants was 72.7 (7.7) years and 57.5% were women. There were no statistically significant differences in change of scores for participants randomized to receive supplements vs those who were not. The yearly change in the composite cognitive function score was −0.19 (99% CI, −0.25 to −0.13) for participants randomized to receive LCPUFAs vs −0.18 (99% CI, −0.24 to −0.12) for those randomized to no LCPUFAs (difference in yearly change, −0.03 [99% CI, −0.20 to 0.13]; P = .63). Similarly, the yearly change in the composite cognitive function score was −0.18 (99% CI, −0.24 to −0.11) for participants randomized to receive lutein/zeaxanthin vs −0.19 (99% CI, −0.25 to −0.13) for those randomized to not receive lutein/zeaxanthin (difference in yearly change, 0.03 [99% CI, −0.14 to 0.19]; P = .66). Analyses were also conducted to assess for potential interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant.
Conclusions and Relevance Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function.
Trial Registration clinicaltrials.gov Identifier: NCT00345176